Brain metastases have long posed a brutal choice for cancer patients: undergo surgery to remove tumors from the brain, then endure weeks of additional radiation therapy to kill remaining cancer cells. But a landmark trial from The University of Texas MD Anderson Cancer Center has revealed a radically different path—one that cuts recovery time from a month to a single day, while slashing recurrence rates by more than 90 percent.
The ROADS trial, led by neurosurgeon Jeffrey Weinberg, M.D., and radiation oncologist Thomas Beckham, M.D., Ph.D., is the first randomized controlled Phase III study to compare tile-based radiation therapy (TBRT) directly against the current standard of care. The innovation sounds almost elegant in its simplicity: surgeons implant tiny collagen tiles—each about the size of a postage stamp—directly into the surgical cavity where the tumor was removed. These tiles, developed by GT Medical Technologies and already FDA-cleared, contain cesium-131 seeds that deliver low-dose therapeutic radiation evenly across the wound surface over several weeks, targeting exactly where microscopic tumor cells are most likely to hide.
The results, presented at the 2026 American Society of Clinical Oncology Annual Meeting, are staggering. After one year, patients treated with TBRT had a 1.3 percent recurrence rate at the surgical site, compared to 15.4 percent of patients who received standard postoperative stereotactic radiation therapy. That's not incremental progress—that's a near-elimination of one of cancer surgery's most common complications. More striking still: median overall survival nearly doubled, reaching 42.5 months with TBRT versus 17.6 months with standard care.
What sets this apart isn't just efficacy. The speed of treatment reshapes the entire patient experience. Most TBRT patients complete their radiation therapy in a single day—the day of surgery itself. Those receiving standard postoperative stereotactic radiation therapy faced a median of 32 days scheduling and traveling for appointments. That month-long gap isn't merely inconvenient; it delays the systemic cancer treatments that address tumors elsewhere in the body. For patients already fighting advanced cancer with tumors in multiple locations, every week matters.
The safety profile proved equally reassuring. Serious side effects occurred at nearly identical rates between the two groups. Radiation necrosis—a late complication where healthy brain tissue dies from radiation exposure—appeared at virtually the same frequency in both arms. The physics explains why: because brachytherapy creates an extremely steep dose gradient, radiation intensity drops off rapidly just beyond the surgical cavity, exposing much less healthy brain tissue to significant radiation than external beam approaches.
"From a patient standpoint, we're showing that there's almost four times the length of local control and an increase in overall survival," Weinberg said. "It's not just a little difference. It's a massive difference."
These results carry particular weight because brain metastases affect thousands of cancer patients annually across multiple tumor types. The ability to eliminate the complication most patients fear—tumor regrowth requiring additional surgery or radiation—while simultaneously freeing them from weeks of postoperative treatment scheduling could reshape how neurosurgeons and oncologists approach these cases. The researchers now hope these findings will accelerate adoption into clinical guidelines and broader hospital practice. Future studies may expand TBRT's use to other tumor types, but for now, brain metastasis patients have been given something rare in oncology: a genuinely transformative option.